Ieq Capital LLC Purchases 24,977 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Ieq Capital LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 57.2% during the fourth quarter, HoldingsChannel reports. The fund owned 68,637 shares of the biopharmaceutical company’s stock after buying an additional 24,977 shares during the quarter. Ieq Capital LLC’s holdings in Regeneron Pharmaceuticals were worth $52,979,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. WPG Advisers LLC grew its position in Regeneron Pharmaceuticals by 312.5% during the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 25 shares during the last quarter. Board of the Pension Protection Fund bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth $31,000. Entrust Financial LLC bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth $32,000. MCF Advisors LLC grew its position in Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 15 shares during the last quarter. Finally, Torren Management LLC bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth $38,000. Institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Royal Bank Of Canada reduced their price objective on Regeneron Pharmaceuticals from $762.00 to $707.00 and set a “sector perform” rating on the stock in a research report on Monday, May 18th. Barclays cut their target price on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a report on Thursday, April 30th. Citigroup downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the stock from $900.00 to $700.00 in a report on Monday, May 18th. Morgan Stanley lifted their target price on Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. Finally, JPMorgan Chase & Co. cut their target price on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a report on Monday, May 18th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $792.65.

Regeneron Pharmaceuticals Stock Up 0.1%

Shares of REGN opened at $612.14 on Friday. The company has a market capitalization of $64.72 billion, a PE ratio of 14.92, a PEG ratio of 1.34 and a beta of 0.25. Regeneron Pharmaceuticals, Inc. has a 12 month low of $503.25 and a 12 month high of $821.11. The stock’s 50-day moving average price is $692.11 and its two-hundred day moving average price is $738.16. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping the consensus estimate of $8.91 by $0.56. The firm had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business’s quarterly revenue was up 19.0% compared to the same quarter last year. During the same period in the previous year, the business earned $8.22 EPS. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is currently 9.16%.

Insider Activity

In other news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $705.24, for a total value of $70,524.00. Following the transaction, the director directly owned 17,503 shares of the company’s stock, valued at $12,343,815.72. The trade was a 0.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by corporate insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.